Fig. 1From: Patient engagement in clinical trial design for rare neuromuscular disorders: impact on the DELIVER and ACHIEVE clinical trialsFramework for Dyne planning, execution, and interpretation of engagement activities (* At the time of this analysis, only the Duchenne CAB was providing consultation to Dyne as a DM1 CAB had not yet been formed)Back to article page